bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
090-70-8402

Order Name:
Aquaporin 4 (AQP4) antibodies, CSF

 
Useful For:
Diagnosis of neuromyelitis optica (NMO, opticospinal encephalomyelitis, Devic's syndrome).
 
Methodology:
Indirect immunofluorescence assay
 
AliasesName:
Aquaporin
AQP4
Optic Neuritis Antibody
NMO (Neruomyelitis Optica)
NMO-IgG
Transverse Myelitis Antibody
Devic's Antibody
 
 
 
Test Code:
090-70-8402

Order Name:
Aquaporin 4 (AQP4) antibodies, CSF

 
Collection Specimen Or Container:
CSF/ Sterile Container
 
Specimen Testing Type:
CSF, minimum volume 0.1 mL
 
Sub Mission Container:
Sterile Container
 
Rejection Criteria:
Hemolysis: N/A
Lipemia: N/A
Icterus: N/A
Other: CSF is mixed with anticoagulants upon collection will be reject.
 
Specimen Stabillity:
Specimen Type Temperature Time
CSF Refrigerated, 2oC to 8oC 14 days
 
 
 
Test Code:
090-70-8402

Order Name:
Aquaporin 4 (AQP4) antibodies, CSF

 
Method detail:
Indirect immunofluorescence assay
 
Schedule:
Test daily, at 03:00 p.m.
 
Turnaround Time:
Received specimen to reported within 2 days.
 
Performing Location:
Molecular biology & Genetics, Laboratory Department Tel.14168
 
Specimen Retention Time:
7 days
 
 
 
Test Code:
090-70-8402

Order Name:
Aquaporin 4 (AQP4) antibodies, CSF

 
 
Clinical Information:
The inflammatory autoimmune disease neuromyelitis optica (NMO, opticospinal encephalomyelitis, Devic's syndrome) is a rare form (around 1%) of the group of acquired demyelinating diseases of the central nervous system (CNS) with degradation of the insulating sheath of at least one optical nerve (neuritis nervi optici) and at the same time of a few months later the spinal cord (myelitis). Diagnosis is made mostly clinically with anamnesis, neurological and neurophysiological tests, MRT of the CNS and lumbar puncture. The diagnosis NMO is confirmed in laboratory diagnostics by the determination of autoantibodies against AQP-4. The major significance of the autoantibody detection is that autoantibodies against AQP-4 (NMO-IgG) allow serological differentiation of prognostically poor NMO from classic multiple sclerosis (MS), which can influence therapy decisions significantly. While MS is treated with immune-modulating substances, NMO requires the use of immuno-suppressive drugs.
 
Reference Value:
Negative
 
Interpretation:
Autoantibodies against AQP-4 are highly specific serum autoantibody markers which are found very frequently in NMO, while they are not detected in multiple sclerosis (MS) patients or in healthy subjects. AQP-4 IgG may be associated with other autoantibodies, such as those against the cell nucleus (ANA), SS-A (Ro) or thyroperoxidase (TPO). This suggests that NMO can occur together with autoimmun diseases such as systemic lupus erythematosus (SLE), Sjogren's Syndrome, etc. A diagnosis should not be made based on a single test result. The clinical symptoms of the patient should always be taken into account along with the serological results by the physician.
 
Clinical Reference:
Manufacturer’s package insert, Anti-Aquaporin-4 IIFT Instruction for the indirect immunofluorescence test, March 2019, EUROIMMUN, D-23560 Lübeck Germany.